Skip to main content
. 2008 Jul 23;2(3):272–281. doi: 10.1016/j.molonc.2008.07.003

Figure 5.

Figure 5

IL‐8 secretion from cell lines. (A) Effects of dasatinib and nilotinib treatment on IL‐8 secretion from K562 and U937 cells. (B) Effects of dasatinib and nilotinib treatment on IL‐8 secretion from UT7 and UT7 cells expressing Bcr–Abl (UT7‐p210). For both panels, cells were either mock treated or treated with 100nM dasatinib or 1μM nilotinib for 3h, 9h or 24h. The supernatants were examined for IL‐8 concentration using an IL‐8 ELISA. The results were normalized to the cell number and supernatant volume in the respective experiment and averages and standard deviation of a representative experiment done in triplicates is shown.